Free Trial

Galmed Pharmaceuticals (GLMD) Earnings Date, Estimates & Call Transcripts

Galmed Pharmaceuticals logo
$2.77 -0.19 (-6.42%)
(As of 02:38 PM ET)

Galmed Pharmaceuticals Latest Earnings Summary

Upcoming Q3
Earnings Date
Nov. 27Estimated
Actual EPS
(Aug. 28)
$2.16 Beat By $2.16

Galmed Pharmaceuticals announced Q2 2024 earnings on August 28, 2024, reporting an EPS of $2.16. Galmed Pharmaceuticals currently has a trailing EPS of -$16.66

GLMD Upcoming Earnings

Galmed Pharmaceuticals' next earnings date is estimated for Wednesday, November 27, 2024, based off prior year's reporting schedules.

Get Galmed Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galmed Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

GLMD Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

GLMD Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Galmed Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
11/27/2024
(Estimated)
------- 
8/28/2024Q2 2024-$2.16+$2.16$2.16--
5/30/2024Q1 2024--$2.76 -$2.76-$0.23--
4/4/2024Q4 2023--$11.76 -$11.76-$0.98--
11/22/2023Q3 2023--$2.88 -$2.88-$0.24--
8/9/2023Q2 2023--$11.40 -$11.40-$0.95--
6/1/2023Q1 2023-$18.00-$13.08+$4.92-$1.09--
3/29/2023Q4 2022--$18.00 -$18.00-$0.10--


This page (NASDAQ:GLMD) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners